Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis

Gastrointestinal Cancer

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

Eur J Cancer

Weiss L, Stintzing S, Modest DP, Stahler A, von Weikersthal LF, Reinacher-Schick A, Decker T, Probst V, Heinrich K, Schwaner I, Kaiser F, Pihusch R, Fuchs M, Held S, Alig A, Gruenberger B, Prager GW, Tougeron D, Taieb J, Heinemann V

doi: 10.1016/j.ejca.2025.116105

Leukemia

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL

Blood

Burger JA, Barr PM, Robak T Prof, Owen C, Tedeschi A, Sarma A, Patten PE, Grosicki S, McCarthy H Dr, Offner F, Szafer Glusman E, Zhou C, Szoke A, Neumayr L, Dean JP, Ghia P, Kipps T

doi: 10.1182/blood.2024028205

Genitourinary Cancer

First-Line Systemic Treatments for Metastatic Hormone-Sensitive Prostate Cancer: Updated Systematic Review and Network Meta-analysis

J Urol

Miyajima K, Miszczyk M, Matsukawa A, Roessler N, Inoue S, Urabe F, Mori K, Yanagisawa T, Karakiewicz PI, Agarwal N, Briganti A, Kimura T, Shariat SF

doi: 10.1097/JU.0000000000005131

Leukemia

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group

Leuk Lymphoma

Zielonka K, Izdebski B, Drozd-Sokołowska J, Pruszczyk-Matusiak K, Puła B, Wiśniewski K, Sawicki W, Kalicińska E, Jabłonowska-Babij P, Butrym A, Buczek T, Subocz E, Hałka J, Witkowska M, Wilk M, Hryniewiecka M, Gruenpeter K, Cichocka E, Halicki P, Wdowiak K, Iskierka-Jażdżewska E, Kopińska A, Szlauer-Stefańska A, Szymczyk A, Wolska-Washer A, Kowalczyk J, Wróbel T, Hus I, Jamroziak K

doi: 10.1080/10428194.2025.2535693

Myeloproliferative Neoplasms (MPNs)

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom

Br J Haematol

Rampotas A, Naylor-Layland G, Brown C, Alabdulkarim A, Ryan J, Wadelin F, Alimam S, Tun PWW, Lambert J, O'Sullivan J, Wilson AJ, Tafesh L, McGregor A, Claudiani S, Innes A, Booth E, Leveson J, Knapper S, Garg M, Dubey M, Vatopoulou T, Brierley C, Leung WKN, Greenfield G, McMullin MF, Khan A, Milne K, Brian D, Godfrey A, Harrison CN, Psaila B, Harrington P, Kirkwood A, Somervaille TCP, McLornan DP, UK Blood Cancer Research Network MPN Clinical Study Group

doi: 10.1111/bjh.70511

Genitourinary Cancer

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial

Ann Oncol

Choueiri TK, Albigès L, McDermott DF, Hammers HJ, Escudier B, Burotto M, Plimack ER, Porta C, George S, Powles T, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Castellano D, Grünwald V, Tomita Y, Rini BI, Jiang R, van Kooten Losio M, Lee CW, Tannir NM, Motzer RJ

doi: 10.1016/j.annonc.2026.02.017

Lung, Respiratory and Thoracic Cancer

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Lung Cancer

Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, Çİl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC

doi: 10.1016/j.lungcan.2026.109302

Gastrointestinal Cancer

Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database

Eur J Cancer

Wagner AD, Raeisi M, Rakez M, Diasio RD, Margalit O, Zalcberg JR, Venook AP, Douillard JY, Lenz HJ, Heinemann V, Goldberg RM, van Cutsem E, Schmoll HJ, Shi Q, André T, de Gramont A

doi: 10.1016/j.ejca.2026.116694